Sangamo’s ST-920 demonstrates evidence of clinical benefit
Phase 1/2 research shows that treatment could be very effective against Fabry disease
Read More
Tag: Sangamo
EU regulators approve Novartis’ breast cancer combo
Piqray in combination with fulvestrant is the first treatment for tumours with a PIK3CA mutation
Read More
Biogen, Sangamo team up on neurological diseases
The companies have detailed plans to leverage Sangamo’s proprietary zinc finger protein (ZFP) technology.
Read More
MHRA authorises in vivo genome editing trial
The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted permission for initiation of Europe’s first in vivo genome editing study.
Read More
Gilead links with Sangamo in gene therapy alliance
Gilead’s Kite is linking with Sangamo Therapeutics in a collaboration that aims to develop next-generation engineered cell therapies for the treatment of cancer.
Read More
Pfizer, Sangamo to work on gene therapies for ALS, FTLD
Pfizer and Sangamo Therapeutics are linking arms to develop a potential gene therapy to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD).
Read More
FDA to fast-track Pfizer/Sangamo gene therapy orphan drug
SB-525 is being developed to treat haemophilia A
Read More
Pfizer strikes gene therapy deal with Sangamo
Says one of the candidates included has best-in-class potential
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
